Novavax (NVAX) Revenue (2010 - 2026)

Novavax's Revenue history runs 17 years deep, the most recent figure standing at $139.5 million for Q1 2026.

• In Q1 2026, Revenue fell 79.07% year-over-year to $139.5 million; the TTM figure through Mar 2026 stood at $532.1 million (down 57.6% YoY), while the FY2025 annual figure was $1.1 billion, up 64.69% from the prior year.
• Revenue was $139.5 million for Q1 2026 at Novavax, down from $147.1 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $734.6 million in Q3 2022 to a low of $70.4 million in Q3 2025.
• Historically, Revenue has averaged $285.1 million across 5 years, with a median of $185.9 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Revenue tumbled 88.5% in 2023, then soared 610.3% in 2025.
• A 5-year view of Revenue shows it stood at $357.4 million in 2022, then fell by 18.48% to $291.3 million in 2023, then slumped by 69.69% to $88.3 million in 2024, then surged by 66.61% to $147.1 million in 2025, then declined by 5.18% to $139.5 million in 2026.
• The last three Revenue figures came in at $139.5 million (Q1 2026), $147.1 million (Q4 2025), and $70.4 million (Q3 2025), per Business Quant data.